Maria Adelaide Caligo

List of Publications by Year in Descending Order

158 papers	6,303 citations	44 h-index	75 g-index
166 ext. papers	7,588 ext. citations	7.1 avg, IF	4.17 L-index

#	Paper	IF	Citations
158	Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variants.. *Genetics in Medicine*, **2021**,	8.1	2
157	Disorders/Differences of Sex Development Presenting in the Newborn With 46,XY Karyotype. *Frontiers in Pediatrics*, **2021**, 9, 627281	3.4	2
156	Longitudinal Lung Volume Changes by Ultrastructure and Genotype in Primary Ciliary Dyskinesia. *Annals of the American Thoracic Society*, **2021**, 18, 963-970	4.7	3
155	The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. *Genetics in Medicine*, **2021**, 23, 1726-1737	8.1	2
154	Detection of Germline Variants in 450 Breast/Ovarian Cancer Families with a Multi-Gene Panel Including Coding and Regulatory Regions. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	1
153	Nutrition, epigenetic markers and growth in preterm infants. *Journal of Maternal-Fetal and Neonatal Medicine*, **2021**, 34, 3963-3968	2	0
152	Disorders of sexual development with XY karyotype and female phenotype: clinical findings and genetic background in a cohort from a single centre. *Journal of Endocrinological Investigation*, **2021**, 44, 145-151	5.2	6
151	A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. *Nature Communications*, **2021**, 12, 1078	17.4	4
150	Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores. *Journal of the National Cancer Institute*, **2021**,	9.7	3
149	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. *Nature Genetics*, **2020**, 52, 572-581	36.3	76
148	Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). *JAMA Oncology*, **2020**, 6, 1218-1230	13.4	25
147	Lung Function Longitudinal Study by Phenotype and Genotype in Primary Ciliary Dyskinesia. *Chest*, **2020**, 158, 117-120	5.3	5
146	Transcriptome-wide association study of breast cancer risk by estrogen-receptor status. *Genetic Epidemiology*, **2020**, 44, 442-468	2.6	9
145	Association of Genomic Domains in and with Prostate Cancer Risk and Aggressiveness. *Cancer Research*, **2020**, 80, 624-638	10.1	22
144	Whole exome sequencing in familial isolated primary hyperparathyroidism. *Journal of Endocrinological Investigation*, **2020**, 43, 231-245	5.2	9
143	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. *Nature Genetics*, **2020**, 52, 56-73	36.3	56
142	Effect of BRCA1 missense variants on gene reversion in DNA double-strand break repair mutants and cell cycle-arrested cells of Saccharomyces cerevisiae. *Mutagenesis*, **2020**, 35, 189-195	2.8	4

141	PROMs in post-mastectomy care: Patient self-reports (BREAST-Q) as a powerful instrument to personalize medical services. *European Journal of Surgical Oncology*, **2020**, 46, 1034-1040	3.6	8
140	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. *Genetics in Medicine*, **2020**, 22, 1653-1666	8.1	34
139	Germline investigation in male breast cancer of DNA repair genes by next-generation sequencing. *Breast Cancer Research and Treatment*, **2019**, 178, 557-564	4.4	18
138	Shared heritability and functional enrichment across six solid cancers. *Nature Communications*, **2019**, 10, 431	17.4	45
137	Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification. *Human Mutation*, **2019**, 40, 1557-1578	4.7	52
136	Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. *British Journal of Cancer*, **2019**, 121, 180-192	8.7	13
135	Blepharophimosis, Ptosis, Epicanthus Inversus Syndrome: New Report with a 197-kb Deletion Upstream of and Review of the Literature. *Molecular Syndromology*, **2019**, 10, 147-153	1.5	7
134	Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. *Nature Communications*, **2019**, 10, 1741	17.4	47
133	Paternity in 5-Reductase-2 Deficiency: Report of Two Brothers with Spontaneous or Assisted Fertility and Literature Review. *Sexual Development*, **2019**, 13, 55-59	1.6	4
132	The :p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. *Npj Breast Cancer*, **2019**, 5, 38	7.8	12
131	Mouse mammary tumor virus (MMTV) - like exogenous sequences are associated with sporadic but not hereditary human breast carcinoma. *Aging*, **2019**, 11, 7236-7241	5.6	11
130	Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. *Journal of the National Cancer Institute*, **2019**, 111, 350-364	9.7	22
129	Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. *Human Mutation*, **2018**, 39, 593-620	4.7	138
128	A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. *Cancer Research*, **2018**, 78, 5419-5430	10.1	32
127	Next generation sequencing technologies for a successful diagnosis in a cold case of Leigh syndrome. *BMC Neurology*, **2018**, 18, 99	3.1	9
126	Genetic Testing and Clinical Management Practices for Variants in Non-BRCA1/2 Breast (and Breast/Ovarian) Cancer Susceptibility Genes: An International Survey by the Evidence-Based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) Clinical Working Group. *JCO Precision Oncology*, **2018**, 2,	3.6	12
125	Functional Interaction Between and DNA Repair in Yeast May Uncover a Role of , and Somatic Variants in Cancer Development. *Frontiers in Genetics*, **2018**, 9, 397	4.5	12
124	BRCA1 and BRCA2 5noncoding region variants identified in breast cancer patients alter promoter activity and protein binding. *Human Mutation*, **2018**, 39, 2025-2039	4.7	12

123	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. *Nature Genetics*, **2017**, 49, 680-691	36.3	190
122	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. *Nature Genetics*, **2017**, 49, 1767-1778	36.3	186
121	Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. *Journal of Clinical Oncology*, **2017**, 35, 2240-2250	2.2	101
120	Whole-exome analysis of a Li-Fraumeni family trio with a novel TP53 PRD mutation and anticipation profile. *Carcinogenesis*, **2017**, 38, 938-943	4.6	6
119	Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. *Breast Cancer Research and Treatment*, **2017**, 161, 117-134	4.4	15
118	Carcinosarcoma of the Breast: An Aggressive Subtype of Metaplastic Cancer. Report of a Rare Case in a Young BRCA-1 Mutated Woman. *Clinical Breast Cancer*, **2017**, 17, e31-e35	3	4
117	Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers. *Journal of the National Cancer Institute*, **2017**, 109,	9.7	153
116	Myelodysplastic syndromes: advantages of a combined cytogenetic and molecular diagnostic workup. *Oncotarget*, **2017**, 8, 79188-79200	3.3	5
115	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. *Gynecologic Oncology*, **2016**, 141, 386-401	4.9	15
114	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. *Nature Communications*, **2016**, 7, 11375	17.4	64
113	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. *Nature Genetics*, **2016**, 48, 374-86	36.3	93
112	Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. *PLoS ONE*, **2016**, 11, e0158801	3.7	7
111	Germline mutations in DNA repair genes may predict neoadjuvant therapy response in triple negative breast patients. *Genes Chromosomes and Cancer*, **2016**, 55, 915-924	5	13
110	Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. *Breast Cancer Research*, **2016**, 18, 15	8.3	58
109	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. *Nature Genetics*, **2015**, 47, 164-71	36.3	177
108	BRCA1 gene variant p.P142H associated with male breast cancer: a two-generation genealogic study and literature review. *Familial Cancer*, **2015**, 14, 515-9	3	
107	FANCM c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor. *Human Molecular Genetics*, **2015**, 24, 5345-55	5.6	68
106	Identification of BRAF 3′UTR Isoforms in Melanoma. *Journal of Investigative Dermatology*, **2015**, 135, 1694-1697	4.3	11

105	Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. *JAMA - Journal of the American Medical Association*, **2015**, 313, 1347-61	27.4	286
104	Expression of human poly (ADP-ribose) polymerase 1 in Saccharomyces cerevisiae: Effect on survival, homologous recombination and identification of genes involved in intracellular localization. *Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis*, **2015**, 774, 14-24	3.3	7
103	MSH2 role in BRCA1-driven tumorigenesis: A preliminary study in yeast and in human tumors from BRCA1-VUS carriers. *European Journal of Medical Genetics*, **2015**, 58, 531-9	2.6	13
102	Characterization of three alternative transcripts of the BRCA1 gene in patients with breast cancer and a family history of breast and/or ovarian cancer who tested negative for pathogenic mutations. *International Journal of Molecular Medicine*, **2015**, 35, 950-6	4.4	15
101	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. *Breast Cancer Research*, **2015**, 17, 61	8.3	16
100	Comparison of mRNA splicing assay protocols across multiple laboratories: recommendations for best practice in standardized clinical testing. *Clinical Chemistry*, **2014**, 60, 341-52	5.5	53
99	Association of SULT1A1 Arg□□His polymorphism with male breast cancer risk: results from a multicenter study in Italy. *Breast Cancer Research and Treatment*, **2014**, 148, 623-8	4.4	4
98	Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. *Breast Cancer Research*, **2014**, 16, 3416	8.3	46
97	Identification of two novel BRCA1-partner genes in the DNA double-strand break repair pathway. *Breast Cancer Research and Treatment*, **2013**, 141, 515-22	4.4	4
96	Performance of BOADICEA and BRCAPRO genetic models and of empirical criteria based on cancer family history for predicting BRCA mutation carrier probabilities: a retrospective study in a sample of Italian cancer genetics clinics. *Breast*, **2013**, 22, 1130-5	3.6	16
95	Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. *PLoS Genetics*, **2013**, 9, e1003212	6	209
94	Effect of the expression of BRCA2 on spontaneous homologous recombination and DNA damage-induced nuclear foci in Saccharomyces cerevisiae. *Mutagenesis*, **2013**, 28, 187-95	2.8	15
93	BRCA1 and BRCA2 germline mutations in Moroccan breast/ovarian cancer families: novel mutations and unclassified variants. *Gynecologic Oncology*, **2012**, 125, 687-92	4.9	46
92	Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. *Breast Cancer Research*, **2012**, 14, R33	8.3	70
91	Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. *Human Mutation*, **2012**, 33, 690-702	4.7	31
90	Effects of BRCA2 cis-regulation in normal breast and cancer risk amongst BRCA2 mutation carriers. *Breast Cancer Research*, **2012**, 14, R63	8.3	15
89	Evaluation of chromosome 6p22 as a breast cancer risk modifier locus in a follow-up study of BRCA2 mutation carriers. *Breast Cancer Research and Treatment*, **2012**, 136, 295-302	4.4	3
88	Effects on human transcriptome of mutated BRCA1 BRCT domain: a microarray study. *BMC Cancer*, **2012**, 12, 207	4.8	3

87	Breast cancer risk and 6q22.33: combined results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2. *PLoS ONE*, **2012**, 7, e35706	3.7	10
86	The KL-VS sequence variant of Klotho and cancer risk in BRCA1 and BRCA2 mutation carriers. *Breast Cancer Research and Treatment*, **2012**, 132, 1119-26	4.4	7
85	A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers. *Cancer Epidemiology Biomarkers and Prevention*, **2012**, 21, 1362-70	4	20
84	Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. *Cancer Epidemiology Biomarkers and Prevention*, **2012**, 21, 645-57	4	44
83	Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). *Cancer Epidemiology Biomarkers and Prevention*, **2012**, 21, 134-47	4	411
82	Exploring the link between MORF4L1 and risk of breast cancer. *Breast Cancer Research*, **2011**, 13, R40	8.3	16
81	Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. *Breast Cancer Research*, **2011**, 13, R110	8.3	62
80	Evaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2. *British Journal of Cancer*, **2011**, 104, 1356-61	8.7	6
79	A recombination-based method to characterize human BRCA1 missense variants. *Breast Cancer Research and Treatment*, **2011**, 125, 265-72	4.4	6
78	Effect of the overexpression of BRCA2 unclassified missense variants on spontaneous homologous recombination in human cells. *Breast Cancer Research and Treatment*, **2011**, 129, 1001-9	4.4	12
77	Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers. *Human Genetics*, **2011**, 130, 685-99	6.3	15
76	Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. *Human Molecular Genetics*, **2011**, 20, 3304-21	5.6	62
75	Common genetic variation at BARD1 is not associated with breast cancer risk in BRCA1 or BRCA2 mutation carriers. *Cancer Epidemiology Biomarkers and Prevention*, **2011**, 20, 1032-8	4	13
74	The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. *Clinical Cancer Research*, **2011**, 17, 3742-50	12.9	45
73	Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers. *Human Molecular Genetics*, **2011**, 20, 4732-47	5.6	21
72	Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. *Journal of the National Cancer Institute*, **2011**, 103, 105-16	9.7	37
71	Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer. *PLoS Biology*, **2011**, 9, e1001199	9.7	73
70	A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. *Nature Genetics*, **2010**, 42, 885-92	36.3	276

69	Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. *Cancer Research*, **2010**, 70, 9742-54	10.1	147
68	Evidence for SMAD3 as a modifier of breast cancer risk in BRCA2 mutation carriers. *Breast Cancer Research*, **2010**, 12, R102	8.3	21
67	Feline immunodeficiency virus vector as a tool for preventative strategies against human breast cancer. *Veterinary Immunology and Immunopathology*, **2010**, 134, 132-7	2	4
66	PALB2: a novel inactivating mutation in a Italian breast cancer family. *Familial Cancer*, **2010**, 9, 531-6	3	30
65	Multimodal assessment of protein functional deficiency supports pathogenicity of BRCA1 p.V1688del. *Cancer Research*, **2009**, 69, 7030-7	10.1	15
64	Two mutations of BRCA2 gene at exon and splicing site in a woman who underwent oncogenetic counseling. *Annals of Oncology*, **2009**, 20, 874-8	10.3	20
63	Reply to BRCA2 splice site mutations in an Italian breast/ovarian cancer family. *Annals of Oncology*, **2009**, 20, 1285-1286	10.3	
62	Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. *Human Molecular Genetics*, **2009**, 18, 4442-56	5.6	91
61	PIK3CA in breast carcinoma: a mutational analysis of sporadic and hereditary cases. *Diagnostic Molecular Pathology*, **2009**, 18, 200-5		31
60	A yeast recombination assay to characterize human BRCA1 missense variants of unknown pathological significance. *Human Mutation*, **2009**, 30, 123-33	4.7	30
59	No evidence that GATA3 rs570613 SNP modifies breast cancer risk. *Breast Cancer Research and Treatment*, **2009**, 117, 371-9	4.4	10
58	Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA). *British Journal of Cancer*, **2009**, 101, 2048-54	8.7	13
57	Characterisation of gene expression profiles of yeast cells expressing BRCA1 missense variants. *European Journal of Cancer*, **2009**, 45, 2187-96	7.5	4
56	Reconstructing the genealogy of a BRCA1 founder mutation by phylogenetic analysis. *Annals of Human Genetics*, **2008**, 72, 310-8	2.2	17
55	Choroid plexus carcinoma: a new case associated with a novel TP53 germ line mutation. *Neuropathology and Applied Neurobiology*, **2008**, 34, 564-8	5.2	5
54	A novel breast cancer-associated BRIP1 (FANCJ/BACH1) germ-line mutation impairs protein stability and function. *Clinical Cancer Research*, **2008**, 14, 4672-80	12.9	46
53	Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. *American Journal of Human Genetics*, **2008**, 82, 937-48	11	218
52	Cancer risk among the relatives of patients with pancreatic ductal adenocarcinoma. *Pancreatology*, **2007**, 7, 459-69	3.8	39

51	High level of messenger RNA for BRMS1 in primary breast carcinomas is associated with poor prognosis. *International Journal of Cancer*, **2007**, 120, 1169-78	7.5	28
50	Identification of novel alternatively spliced BRCA1-associated RING domain (BARD1) messenger RNAs in human peripheral blood lymphocytes and in sporadic breast cancer tissues. *Genes Chromosomes and Cancer*, **2007**, 46, 791-5	5	10
49	Association between the BRCA2 N372H variant and male breast cancer risk: a population-based case-control study in Tuscany, Central Italy. *BMC Cancer*, **2007**, 7, 170	4.8	21
48	Methyl group metabolism gene polymorphisms as modifier of breast cancer risk in Italian BRCA1/2 carriers. *Breast Cancer Research and Treatment*, **2007**, 103, 29-36	4.4	22
47	Multicenter comparative multimodality surveillance of women at genetic-familial high risk for breast cancer (HIBCRIT study): interim results. *Radiology*, **2007**, 242, 698-715	20.5	287
46	RNA-based analysis of BRCA1 and BRCA2 gene alterations. *Cancer Genetics and Cytogenetics*, **2006**, 170, 93-101		40
45	Aberrant expression of BARD1 in breast and ovarian cancers with poor prognosis. *International Journal of Cancer*, **2006**, 118, 1215-26	7.5	55
44	Genetic alterations in hereditary breast cancer. *Annals of Oncology*, **2004**, 15 Suppl 1, I7-I13	10.3	39
43	Evaluation of widely used models for predicting BRCA1 and BRCA2 mutations. *Journal of Medical Genetics*, **2004**, 41, 278-85	5.8	50
42	Haplotype analysis of BRCA1 gene reveals a new gene rearrangement: characterization of a 19.9 KBP deletion. *European Journal of Human Genetics*, **2004**, 12, 775-7	5.3	15
41	Penetrances of breast and ovarian cancer in a large series of families tested for BRCA1/2 mutations. *European Journal of Human Genetics*, **2004**, 12, 899-906	5.3	46
40	Clinicopathological significance of GADD45 gene alterations in human familial breast carcinoma. *Breast Cancer Research and Treatment*, **2004**, 87, 197-201	4.4	5
39	The CHEK2 c.1100delC mutation plays an irrelevant role in breast cancer predisposition in Italy. *Human Mutation*, **2004**, 24, 100-1	4.7	36
38	Different expressivity of BRCA1 and BRCA2: analysis of 179 Italian pedigrees with identified mutation. *Breast Cancer Research and Treatment*, **2003**, 81, 71-9	4.4	22
37	p53 inactivation is a rare event in familial breast tumors negative for BRCA1 and BRCA2 mutations. *Breast Cancer Research and Treatment*, **2003**, 82, 1-9	4.4	14
36	Germline mutations of the BRCA1-associated ring domain (BARD1) gene in breast and breast/ovarian families negative for BRCA1 and BRCA2 alterations. *Genes Chromosomes and Cancer*, **2002**, 33, 235-42	5	93
35	Mutational analysis of the NM23.H1 gene in human breast cancer. *Cancer Genetics and Cytogenetics*, **2000**, 121, 181-5		5
34	The Exon 13 Duplication in the BRCA1 Gene Is a Founder Mutation Present in Geographically Diverse Populations. *American Journal of Human Genetics*, **2000**, 67, 207-212	11	89

33	Cyclin D1 overexpression in thyroid carcinomas: relation with clinico-pathological parameters, retinoblastoma gene product, and Ki67 labeling index. *Thyroid*, **2000**, 10, 741-6	6.2	44
32	Microsatellite alterations and K-ras, TGFbetaRII, IGFRII and bax mutations in sporadic cancers of the gastrointestinal tract. *Oncology Reports*, **2000**, 7, 1371-5	3.5	10
31	Mutation Analysis of BRCA1 and BRCA2 in Italian Hereditary and Sporadic Forms of Breast and Ovarian Cancers: Tumor Genotype-Phenotype Correlation in Breast Cancer BRCA-Mutation Carriers. *Disease Markers*, **1999**, 15, 101-102	3.2	1
30	Insurance implications for individuals with a high risk of breast and ovarian cancer in Europe. *Disease Markers*, **1999**, 15, 159-65	3.2	10
29	Genetic testing for breast cancer predisposition in 1999: which molecular strategy and which family criteria?. *Disease Markers*, **1999**, 15, 67-8	3.2	4
28	Ethical, social and economic issues in familial breast cancer: a compilation of views from the E.C. Biomed II Demonstration Project. *Disease Markers*, **1999**, 15, 125-31	3.2	23
27	Risk estimation as a decision-making tool for genetic analysis of the breast cancer susceptibility genes. EC Demonstration Project on Familial Breast Cancer. *Disease Markers*, **1999**, 15, 53-65	3.2	7
26	Microsatellite instability and mismatch repair gene inactivation in sporadic pancreatic and colon tumours. *British Journal of Cancer*, **1999**, 80, 11-6	8.7	56
25	Microsatellite alterations and p53, TGFbetaRII, IGFIIR and BAX mutations in sporadic non-small-cell lung cancer. *International Journal of Cancer*, **1998**, 78, 606-9	7.5	10
24	Current policies for surveillance and management in women at risk of breast and ovarian cancer: a survey among 16 European family cancer clinics. European Familial Breast Cancer Collaborative Group. *European Journal of Cancer*, **1998**, 34, 1922-6	7.5	98
23	Haplotype and phenotype analysis of nine recurrent BRCA2 mutations in 111 families: results of an international study. *American Journal of Human Genetics*, **1998**, 62, 1381-8	11	138
22	A region on the long arm of chromosome 16 is frequently deleted in metastatic node-negative breast cancer. *International Journal of Oncology*, **1998**, 13, 177-82	1	4
21	NM23 gene expression in human breast carcinomas: loss of correlation with cell proliferation in the advanced phase of tumor progression. *International Journal of Cancer*, **1997**, 74, 102-11	7.5	23
20	Down-regulation of the nm23.h1 gene inhibits cell proliferation. *International Journal of Cancer*, **1997**, 73, 297-302	7.5	40
19	Down regulation of NM23.H1, NM23.H2 and c-myc genes during differentiation induced by 1,25 dihydroxyvitamin D3. *Leukemia Research*, **1996**, 20, 161-7	2.7	32
18	Defective interleukin six expression and responsiveness in human mammary cells transformed by an adeno 5/SV40 hybrid virus. *British Journal of Cancer*, **1996**, 73, 1356-61	8.7	12
17	BRCA1 germline mutational spectrum in Italian families from Tuscany: a high frequency of novel mutations. *Oncogene*, **1996**, 13, 1483-8	9.2	36
16	NM23 gene expression correlates with cell growth rate and S-phase. *International Journal of Cancer*, **1995**, 60, 837-42	7.5	60

15	A low NM23.H1 gene expression identifying high malignancy human melanomas. *Melanoma Research*, **1994**, 4, 179-84	3.3	21
14	NM23.H1 loss of heterozygosity in human mammary carcinomas. Definition of a deletion map on chromosome 17q. *Annals of the New York Academy of Sciences*, **1993**, 698, 136-42	6.5	4
13	Accumulation of anchorage independent cells showing amplified genes (CAD) during the in vitro propagation of CHEF18 Chinese hamster cells. *Cell Proliferation*, **1993**, 26, 161-70	7.9	4
12	Genomic PCR-SSCP analysis of the metastasis associated NM23-H1 (NME1) gene: a study on colorectal cancer. *Anticancer Research*, **1993**, 13, 2149-54	2.3	8
11	The NM23 gene maps to human chromosome band 17q22 and shows a restriction fragment length polymorphism with BglII. *Genes Chromosomes and Cancer*, **1992**, 4, 84-8	5	49
10	Decreasing expression of NM23 gene in metastatic murine mammary tumors of viral etiology (MMTV). *Anticancer Research*, **1992**, 12, 969-73	2.3	14
9	Increased rate of base substitution in a hamster mutator strain obtained during serial selection for gene amplification. *Molecular and Cellular Biology*, **1990**, 10, 6805-8	4.8	8
8	Increased rate of base substitution in a hamster mutator strain obtained during serial selection for gene amplification. *Molecular and Cellular Biology*, **1990**, 10, 6805-6808	4.8	3
7	Time course of sister chromatid exchanges and gene amplification induced by 1-beta-D-arabinofuranosylcytosine in V79-AP4 Chinese hamster cells. *Chromosoma*, **1988**, 96, 306-10	2.8	6
6	Origin of araC-induced endoreduplicated cells. *Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis*, **1987**, 177, 261-5	3.3	10
5	Proline and serine affect polarity and development of carrot somatic embryos. *Cell Differentiation*, **1985**, 17, 193-198		14
4	Stimulation of carrot somatic embryogenesis by proline and serine. *Plant Cell Reports*, **1984**, 3, 210-4	5.1	50
3	Polygenic Risk Modelling for Prediction of Epithelial Ovarian Cancer Risk		1
2	Fine-mapping of 150 breast cancer risk regions identifies 178 high confidence target genes		2
1	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses		2